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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids was requested to
consider evaluations of ﬂavouring substances assessed since 2000 by the Joint FAO/WHO Expert
Committee on Food Additives (JECFA), and to decide whether further evaluation is necessary, as laid
down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a group of four
ﬂavouring substances consisting of isopulegone and three other substances evaluated by JECFA at the
55th meeting. This revision is made due to additional toxicity data available for (1R,2S,5R)-isopulegol
[FL-no: 02.067]. The substances were evaluated through a stepwise approach that integrates information
on structure–activity relationships, intake from current uses, toxicological threshold of concern, and
available data on metabolism and toxicity. p-Mentha-1,4(8)-dien-3-one [FL-no: 07.127] is no longer
supported by the ﬂavour industry and was not evaluated. In agreement with JECFA, the Panel evaluated
the candidate substances in this Flavouring Group Evaluation (FGE) via the B-side of the Procedure.
Based on a no observed adverse effect level (NOAEL) from a 90-day oral toxicity study on [FL-no:
02.067], adequate margins of safety for the three candidate substances could be calculated. Therefore,
the Panel agrees with the JECFA conclusion, ‘No safety concern at estimated levels of intake as ﬂavouring
substances’ based on the maximised survey-derived daily intake (MSDI) approach. Besides the safety
assessment of these ﬂavouring substances, the speciﬁcations for the materials of commerce have also
been considered and found adequate. For the three substances evaluated in this FGE, use levels have
become available and the modiﬁed theoretical added maximum daily intakes (mTAMDIs) were estimated.
For [FL-no: 02.067 and 07.067], the mTAMDI exceeds the toxicological threshold of concern for their
structural classes and need more reﬁned exposure assessment to ﬁnalise the evaluation.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The use of ﬂavourings in food is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20081 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list includes ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
On 29 January 2009, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 57 (FGE.57): Consideration of two
structurally related pulegone metabolites and one ester thereof evaluated by (JECFA) (55th meeting).4
In its opinion, the Panel stated that:
‐ It agreed with the application of the Procedure as performed by the JECFA for the three
substances considered in this FGE until step B3. As no appropriate study could be identiﬁed to
derive a no observed adverse effect level (NOAEL), the Panel concluded at step B4, contrary to
JECFA, that for all three substances [FL-no: 02.067, 07.067 and 09.219] additional toxicity data
are required.
‐ For the three substances [FL-no: 02.067, 07.067 and 09.219], evaluated through the
Procedure, use levels are needed to calculate the modiﬁed theoretical added maximum daily
intakes (mTAMDI) in order to identify those ﬂavouring substances that need more reﬁned
exposure assessment and to ﬁnalise the evaluation.
‐ In order to determine whether the conclusion for the three JECFA evaluated substances can be
applied to the materials of commerce, it is necessary to consider the available speciﬁcations.
Speciﬁcations including purity and identity are available for one JECFA evaluated substance
[FL-no: 07.067]. Information on composition of mixture is incomplete for the other two
substances [FL-no: 02.067 and 09.219].
Thus, the Panel had reservations for all three substances. For two of the three substances, the
composition of the mixture has to be speciﬁed [FL-no: 02.067 and 09.219], and for all three
substances [FL-no: 02.067, 07.067 and 09.219], additional toxicity data are required.
Subsequently, the substances were included in the Union List with a Footnote 4.
On 20 December 2013 and on 29 January 2014, the applicant submitted additional relevant data
for these 3 substances from FGE.57.
Terms of Reference as provided by the European Commission
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this
new information and, depending on the outcome, proceed to the full evaluation on this ﬂavouring
substance in accordance with Commission Regulation (EC) No 1565/2000.
1.2. Interpretation of the Terms of Reference
As additional genotoxicity data have been submitted, the European Commission requests EFSA to
carry out a safety assessment on the ﬂavouring substances [FL-no: 02.067, 07.067 and 09.219] from
FGE.57, in accordance with Commission Regulation (EC) No 1565/2000.
During the genotoxicity evaluation of p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] in FGE.213Rev1
and FGE.213Rev2 (EFSA CEF Panel, 2014, 2015), the Panel noted that the chemical structure of the
ﬂavouring substance is more closely related to the structure of pulegone than to the structures used
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
4 EFSA Journal (2009) ON-1079, 1–17.
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for the read-across approach in FGE.213Rev1. In this case, the Panel decided to include also [FL-no:
07.127] in the present revision of FGE.57Rev1.
p-Mentha-1,4(8)-dien-3-one [FL-no: 07.127] is no longer supported by the ﬂavour industry and will
not be evaluated in the present revision.
2. Assessment
The approach used by EFSA for the safety evaluation of ﬂavouring substances is referred to in
Commission Regulation (EC) No 1565/2000, hereafter named the ‘EFSA Procedure’ (Appendix A). This
Procedure is based on the Opinion of the Scientiﬁc Committee on Food (SCF, 1999), which has been
derived from the evaluation procedure developed by Joint FAO/WHO Expert Committee on Food
Additives (JECFA) (1995, 1996, 1997, 1999), hereafter named the ‘JECFA Procedure’. The Panel on
Food Contact Materials, Enzymes, Flavourings and Processing Aids (the Panel) compares the JECFA
evaluation of structurally related substances with the result of a corresponding EFSA evaluation,
focussing on speciﬁcations, intake estimations and toxicity data, especially genotoxicity data. The
evaluations by EFSA will conclude whether the ﬂavouring substances are of no safety concern at their
estimated levels of intake, whether additional data are required or whether certain substances should
not be evaluated through the EFSA Procedure.
The following issues are of special importance.
Intake
In its evaluation, the Panel as a default uses the maximised survey-derived daily intake (MSDI)
approach to estimate the per capita intakes of the ﬂavouring substances in Europe.
In its evaluation, JECFA includes intake estimates based on the MSDI approach derived from both
European and USA production ﬁgures. The highest of the two MSDI ﬁgures is used in the evaluation
by JECFA. It is noted that in several cases, only the MSDI ﬁgures from the USA were available,
meaning that certain ﬂavouring substances have been evaluated by JECFA only on the basis of these
ﬁgures. For Register substances for which this is the case, the Panel will need EU production ﬁgures in
order to ﬁnalise the evaluation.
When the Panel examined the information provided by the European Flavour Industry on the use
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would
grossly underestimate the intake by regular consumers of products ﬂavoured at the use level reported
by Industry, especially in those cases where the annual production values were reported to be small.
In consequence, the Panel had reservations about the data on use and use levels provided and the
intake estimates obtained by the MSDI approach. It is noted that JECFA, at its 65th meeting
considered ‘how to improve the identiﬁcation and assessment of ﬂavouring agents, for which the MSDI
estimates may be substantially lower than the dietary exposures that would be estimated from the
anticipated average use levels in foods’ (JECFA, 2006).
In the absence of more accurate information that would enable the Panel to make a more realistic
estimate of the intakes of the ﬂavouring substances, the Panel has decided also to perform an
estimate of the daily intakes per person using a mTAMDI approach based on the normal use levels
reported by Industry.
As information on use levels for the ﬂavouring substances has not been requested by JECFA or has
not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the
mTAMDI approach for the substances evaluated by JECFA. The Panel will need information on use
levels in order to ﬁnalise the evaluation.
Threshold of 1.5 lg/person per day (step B5) used by JECFA
JECFA uses the threshold of concern of 1.5 microgram (lg)/person per day as part of the
evaluation procedure:
‘The Committee noted that this value was based on a risk analysis of known carcinogens which
involved several conservative assumptions. The use of this value was supported by additional
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the
Committee, ﬂavouring substances for which insufﬁcient data are available for them to be evaluated
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 lg per person per
day would not be expected to present a safety concern. The Committee recommended that the
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended
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to include the last step on the right-hand side of the original procedure (‘Do the condition of use result
in an intake greater than 1.5 lg per day?’) (JECFA, 1999).
In line with the Opinion expressed by the SCF (1999), the Panel does not make use of this
threshold of 1.5 lg/person per day.
Genotoxicity
As reﬂected in the Opinion of the SCF (1999), the Panel has in its evaluation focussed on a possible
genotoxic potential of the ﬂavouring substances or of structurally related substances. Generally,
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided.
Substances for which a genotoxic potential in vivo has been concluded will not be evaluated through
the Procedure.
Speciﬁcations
Regarding speciﬁcations, the evaluation by the Panel could lead to a different opinion than that of
JECFA, since the Panel requests information on e.g. isomerism.
Structural Relationship
In the consideration of the JECFA evaluated substances, the Panel will examine the structural
relationship and metabolism features of the substances within the ﬂavouring group and compare this
with the corresponding FGE.
2.1. History of the evaluation of the substances in the Present FGE
In the scientiﬁc opinion on FGE.57 (EFSA, 2009), the Panel followed the JECFA approach for the
evaluation of [FL-no: 02.067, 07.067 and 09.219] and assessed the substances within the group of
pulegone and menthofuran (JECFA, 2001a). However, none of the three substances is an a,b-
unsaturated compound like pulegone; moreover, there is no convincing evidence that pulegone and
isopulegol are interconverted in vivo (or in vitro) (see Appendix C).
FGE Opinion adopted Link
No. of
substances
FGE.57 29 January 2009 http://www.efsa.europa.eu/en/efsajournal/pub/1079.htm 3
FGE.57Rev1 31 January 2017 http://www.efsa.europa.eu/en/efsajournal/pub/4727.htm 4
For reasons detailed in Sections 2.2.1 and Appendix C, in the present revision of FGE.57, the
Panel decided to deviate from JECFA and its previous evaluations and to no longer use pulegone as a
supporting substance of (1R,2S,5R)-isopulegol [FL-no: 02.067], (2R,5S)-isopulegone [FL-no: 07.067]
and (1R,2S,5R)-isopulegyl acetate [FL-no: 09.219]. Nevertheless, the ﬁndings published on pulegone
by the National Toxicology Program (NTP, 2011), the International Agency for Research on Cancer
(IARC, 2014) and the European Medicines Agency (EMA, 2014) have been taken into consideration.
In 2011, NTP performed subchronic and chronic toxicity studies on pulegone (NTP, 2011),
indicating that pulegone may cause bladder cancer in female rats. Based on the induced gene
mutations observed when pulegone was tested in a bacterial reverse mutation assay, the authors
linked the bladder tumours to the genotoxic potential of pulegone. Considering the above and also the
reports by IARC (2014) and EMA (2014) on pulegone, the Panel concluded that the concern for
genotoxicity of pulegone cannot be ruled out based on the lack of robust data.
In line with the NTP ﬁndings on pulegone and the fact that despite the absence of structural alert
for isopulegone, reactive metabolites raising a genotoxicity concern might be formed from this
substance via epoxidation, the Panel requested the applicant to test isopulegone [FL-no: 07.067] in a
bacterial reverse mutation assay and an in vitro micronucleus assay. Instead of isopulegone [FL-no:
07.067], the ﬂavour industry submitted data on the most available material, isopulegol [FL-no: 02.067]
(EFFA, 2016a). These data were acknowledged and considered by the Panel in the present revision of
FGE.57 (FGE.57Rev1): a bacterial reverse mutation assay (Roy, 2015) and an in vitro micronucleus
assay on (1R,2S,5R)-isopulegol [FL-no: 02.067] (Schulz, 2010).
p-Mentha-1,4(8)-dien-3-one [FL-no: 07.127] is also going to be considered in the present revision
of FGE.57. It is an a,b-unsaturated alicyclic ketone evaluated in FGE.213Rev1, found to be structurally
more closely related to pulegone than the supporting substances used to rule out the concern for
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genotoxicity in FGE.213Rev1 (EFSA CEF Panel, 2014, 2015). Because of its structural alert and
structural similarity with pulegone, the Panel requested additional data on genotoxicity for the
substance [FL-no: 07.127]. Recent communication by the applicant, however, revealed that p-mentha-
1,4(8)-dien-3-one [FL-no: 07.127] is no longer supported by the ﬂavour industry (EFFA, 2016b) and
although included in the present revision, the substance will not be evaluated by the Panel.
In the scientiﬁc opinion on FGE.57, the Panel concluded that no NOAEL could be derived for
(1R,2S,5R)-isopulegol [FL-no: 02.067], (2R,5S)-isopulegone [FL-no: 07.067] and (1R,2S,5R)-isopulegyl
acetate [FL-no: 09.219]. Accordingly, additional toxicity data were requested for the three substances.
In the present revision (FGE.57Rev1), a 14-day range ﬁnding study (Mendes, 2012) and a 90-day
dietary study (Koetzner, 2013) have been provided for (1R,2S,5R)-isopulegol [FL-no: 02.067]. These
studies, covering also the evaluation of the structurally related (2R,5S)-isopulegone [FL-no: 07.067]
and (1R,2S,5R)-isopulegyl acetate [FL-no: 09.219], are evaluated by the Panel.
Information on the stereoisomeric composition of [FL-no: 02.067, 07.067 and 09.219] and their use
levels in food has also become available and included in the present output (EFFA, 2014, 2017).
2.2. Presentation of the substances in the JECFA Flavouring Group
2.2.1. Description
JECFA status
The JECFA Committee (JECFA, 2001a) has evaluated a group of six ﬂavouring substances consisting
of pulegone and ﬁve structurally related substances. The six substances are: pulegone, menthofuran,
p-mentha-1,4-(8)-dien-3-one, (1R,2S,5R)-isopulegol, (2R,5S)-isopulegone and (1R,2S,5R)-isopulegyl
acetate (JECFA-no: 753, 758, 757, 755, 754 and 756).
EFSA considerations
Pulegone (JECFA-no: 753) and menthofuran (JECFA-no: 758) are in Annex III of Regulation (EC)
No 1334/2008 of the European Parliament and of the Council1 and accordingly cannot be used as
chemically deﬁned ﬂavouring substances in the European Union (EU). p-Mentha-1,4(8)-dien-3-one
[FL-no: 07.127] is an a,b-unsaturated ketone which has been considered together with other a,b -
unsaturated ketones in FGE.213Rev1. The Panel decided to include [FL-no: 07.127] in the present
revision of this FGE because of its structural similarity with pulegone. However, meanwhile industry
communicated that the substance is no longer supported (see Section 2.1). Therefore, [FL-no: 07.127]
will not be evaluated by the Panel. Thus, the current revision of FGE.57 deals with the evaluation of
three ﬂavouring substances [FL-no: 02.067, 07.067 and 09.219].
Rational for rejecting pulegone as a supporting substance in this evaluation
Although it has been speculated that (2R,5S)-isopulegone may be isomerised to pulegone (Gordon
et al., 1987; Madyastha and Gaikwad, 1998), there is no convincing evidence for that since no
experimental in vitro or in vivo data on metabolism could be identiﬁed to support the concept of
interconversion of isopulegone to pulegone (for details see Appendix C).
Substances [FL-no: 02.067, 07.067 and 09.219] are not a,b-unsaturated compounds and therefore
not sufﬁciently structurally related to pulegone for the latter to be a supporting substance. The
additional data on genotoxicity submitted for isopulegol [FL-no: 02.067] support this statement (see
Section 4.3). Based on the above, the Panel decided that the ﬁndings on carcinogenicity for pulegone
were not relevant for isopulegone. Consequently, pulegone is no longer considered as a supporting
substance for the isopulegone-related ﬂavouring substances in FGE.57Rev1, contrary to what was
done previously by JECFA (2001a) and the Panel (EFSA, 2009).
2.2.2. Isomers
Status
Substances with [FL-no: 02.067, 07.067 and 09.219] evaluated by JECFA, have one or more chiral
centres.
EFSA considerations
Adequate information on isomeric composition is available for all three substances (Table 1).
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2.2.3. Speciﬁcations
Status
Speciﬁcations for all JECFA substances evaluated in this FGE are reported in Table 1.
EFSA considerations
Speciﬁcations including complete purity criteria and identity are available for all substances
(Table 1).
3. Intake estimation
3.1. Status
For all substances evaluated through the JECFA Procedure production volumes, based on which
MSDI values can be calculated, are available for the EU, see Appendix E, Table E.1.
3.2. EFSA considerations
For all substances, industry has submitted production ﬁgures for the EU.
For (1R,2S,5R)-isopulegol [FL-no: 02.067], (2R,5S)-isopulegone [FL-no: 07.067] and (1R,2S,5R)-
isopulegyl acetate [FL-no: 09.219], the ﬂavour industry submitted use levels for normal and maximum
use (EFFA, 2017). Based on these normal use levels, the mTAMDI values were calculated. Isopulegyl
acetate [FL-no: 09.219] has mTAMDI intake estimate below the threshold of concern for its structural
class. For (1R,2S,5R)-isopulegol [FL-no: 02.067] and (2R,5S)-isopulegone [FL-no: 07.067], the mTAMDI
values are above the toxicological thresholds of concern for their structural classes of 1,800 and
540 lg/person per day, respectively. Therefore, for these two substances, more reliable exposure data
are required in order to ﬁnalise their evaluation. On the basis of such additional data, [FL-no: 02.067
and 07.067] should be reconsidered using the Procedure. Following this procedure, additional
toxicological data might become necessary.
Use levels and mTAMDI values are presented in Appendix B, Tables B.1 and B.2.
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4. Genotoxicity
4.1. Genotoxicity studies considered by JECFA (2001b)
No in vitro or in vivo genotoxicity studies were available on (1R,2S,5R)-isopulegol [FL-no: 02.067],
2R,5S-isopulegone [FL-no: 07.067] and 1R,2S,5R-isopulegyl acetate [FL-no: 09.219]. No conclusion
was made by JECFA with respect to genotoxicity of (1R,2S,5R)-isopulegol [FL-no: 02.067], (2R,5S)-
isopulegone [FL-no: 07.067] and (1R,2S,5R)-isopulegyl acetate [FL-no: 09.219].
4.2. Genotoxicity studies on (1R,2S,5R)-isopulegol [FL-no: 02.067]
4.2.1. Bacterial reverse mutation assay
In order to investigate the potential of isopulegol (purity ≥ 99.4%) and/or its metabolites to induce
gene mutations in bacteria, an Ames test was performed according to OECD Test Guideline 471
(OECD, 1997a) and following Good Laboratory Practice (GLP) in four strains of Salmonella typhimurium
(TA98, TA100, TA1535 and TA1537) and Escherichia coli WP2uvrA, in the presence or absence of
metabolic activation (S9-mix) applying the standard plate incorporation method and the pre-incubation
test (Schulz, 2010). The ﬁrst experiment (plate incorporation) was carried out using six different
concentrations of isopulegol from 33 to 5,000 lg/plate. The second experiment was subsequently
performed using the pre-incubation test at concentrations of 10, 33, 100, 333, 1,000 and 2,500 with
S. typhimurium strains, and 33, 100, 333, 1,000 and 5,000 lg/plate in E. coli. Appropriate positive
control chemicals and dimethyl sulfoxide (DMSO) (as a vehicle control) were evaluated concurrently,
and all test and control articles were evaluated in triplicate plates. All positive control chemicals
induced signiﬁcant increases in revertant colony numbers, conﬁrming the sensitivity of the tests and
the efﬁcacy of the S9-mix, while negative controls were within the historical control ranges. No
precipitate was observed at any tested concentration in any tester strain with or without S9-mix.
Toxicity, as evident by the absence or reduction in the mean number of revertant colonies and the
absence or reduction in the background bacterial lawn, was observed in the plate incorporation test at
2,500 lg/plate and above in all tester strains in the presence and absence of S9-mix; exception were
TA1537 and WP2uvrA showing toxicity at 5,000 lg/plate. Applying the pre-incubation assay, toxicity
was observed at 1,000 lg/plate and above in S. typhimurium strains and 2,500 lg/plate and above in
E. coli.
No increase in the mean number of revertant colonies was observed at any tested concentration in
any tester strains with or without S9-mix.
The Panel considered that isopulegol has no mutagenic activity under the conditions employed.
4.2.2. Micronucleus assay in vitro
Isopulegol (99.4% purity) was assayed for the induction of chromosome damage in mammalian
cells by an in vitro micronucleus assay carried out according to OECD Test Guideline 487 (OECD, 2010)
and following GLP. Human peripheral blood lymphocytes (HPBL) from healthy donors, stimulated with
phytohaemagglutinin (PHA), were treated with isopulegol 48 h after culture initiation either for 4 h in
the absence or presence of S9-mix followed by 20 h recovery or for 24 h in the absence of S9-mix
(Roy, 2015). Cytochalasin B (ﬁnal concentration of 6 lg/mL) was added to each culture after the 3 h
treatment period, while in the 24 h treatment cultures were treated with the test article in the
presence of cytochalasin B. Appropriate vehicle (DMSO) and positive controls were used (mitomycin C
and vinblastine in the short and continuous treatment without S9-mix, respectively; cyclophosphamide
in the short treatment with S9-mix). All positive control compounds induced a statistically signiﬁcant
increase in micronucleus frequency and the system was considered sensitive and valid. One thousand
cells were scored in duplicate cultures (2,000 cells per concentration).
In a preliminary dose-ﬁnding assay, performed at nine concentrations ranging from 0.154 to
1,540 lg/mL (10 mM), cytotoxicity was observed at the highest concentration in the short treatment
with S9-mix and 154 lg/mL and above after continuous treatment. Visible precipitate was observed in
treatment medium at 1,540 lg/mL; at the end of the treatment period, all dose levels were soluble in
treatment medium in all treatment conditions.
The concentration range suitable for the analysis of micronuclei in the main experiment was
selected on the basis of these ﬁndings; however, due to toxicity pattern change, the experiment was
repeated and the ﬁnal concentrations tested in each experimental condition were as follows: (i) 250,
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500, and 700 lg/mL for the short treatment with and without S9-mix; (ii) 25, 50, and 100 lg/mL for
the continuous treatment without S9-mix. The levels of cytotoxicity (based upon cytokinesis-blocked
proliferation index (CBPI)) reached 58%, 57% and 50% at high concentrations in the three
experimental conditions, respectively. In the repeat assay, the test substance was soluble in DMSO and
in the treatment medium at all concentrations tested at the beginning and end of the treatment
period. At the end of the short treatment with and without S9-mix, haemolysis was observed at
concentrations ≥ 900 lg/mL. No marked changes were observed with respect to osmolality and pH.
No statistically signiﬁcant increase in the frequency of micronuclei was observed after treatment with
the test article at any concentration analysed.
The Panel considered that isopulegol did not induce micronuclei in cultured human peripheral blood
lymphocytes under the conditions employed.
Therefore, the Panel concluded that, based on the bacterial gene mutation assay and the in vitro
micronucleus assay, there is no concern with respect to genotoxicity of isopulegol [FL-no: 02.067].
For a summary of in vitro genotoxicity data, see Appendix D, Table D.1.
4.3. EFSA considerations
Based on the results from the bacterial reverse mutation assays and the in vitro micronucleus
assay, there is no concern for genotoxicity of (1R,2S,5R)-isopulegol [FL-no: 02.067] and the
structurally related substances (2R,5S)-isopulegone [FL-no: 07.067] and (1R,2S,5R)-isopulegyl acetate
[FL-no: 09.219].
5. Toxicity data on isopulegol
5.1. 14-Day and 90-day study on (1R,2S,5R)-isopulegol [FL-no: 02.067]
5.1.1. 14-Day oral range-ﬁnding toxicity study
A 14-day range-ﬁnding dietary study was performed with (1R,2S,5R)-isopulegol [FL-no: 02.067]
(Mendes, 2012). The study was not in full compliance with GLP. Moreover, although it was stated to be
performed according to OECD Test Guideline 407 (repeated dose 28-day oral toxicity study in rodents),
a full study according to OECD Test Guideline 407 would encompass a 28-day exposure period and
larger groups of animals. In addition, the number of parameters studied was far more limited than
required for a full OECD Test Guideline 407 study (OECD, 2008).
CRL Sprague–Dawley CD IGS rats (three per sex per group) were exposed to (1R,2S,5R)-
isopulegol (microencapsulated in acacia gum) via the feed at dietary levels of 2,400 (Group 2), 9,000
(Group 3) and 36,000 (Group 4) mg microencapsulated isopulegol-containing acacia gum/kg feed. The
control group received a feed containing 36,000 mg acacia gum/kg feed, (Group 1). The mean overall
(days 0–14) daily intakes of (1R,2S,5R)-isopulegol were 0, 230, 860 and 3,390 mg/kg body weight
(bw) per day, in male rats and 0, 240, 860 and 3,150 mg/kg bw per day for the female animals. The
study report is not explicit as the actual daily intake of isopulegol (neat) by the animals (on a mg/kg
bw per day basis) was not provided.
The test substance was considered stable under the conditions of storage over the course of this
study. Animals were observed daily for viability, signs of gross toxicity and behavioural changes, and on
days 0, 7, and 14 for a battery of detailed observations. Body weights were recorded two times during the
acclimatisation period including prior to test initiation (day 0), and on days 7, 10 and 14 prior to terminal
sacriﬁce. Individual food consumption was also recorded to coincide with body weight measurements. No
other parameters (e.g. urinalysis, haematology, histopathology, biochemistry) were studied.
There were no test substance-related mortalities, clinical signs or macroscopic changes during this
study.
In Group 4, female rats (36,000 mg/kg feed), (1R,2S,5R)-isopulegol resulted in a statistically
signiﬁcant decrease in body weight gain from day 0–7 and for the overall study (days 0–14). Group 4
female rats also demonstrated a statistically signiﬁcant reduction in food efﬁciency for the overall study
(days 0–14). The decrease in Group 4 female rat body weight gain corresponded to reductions in food
consumption and efﬁciency during the ﬁrst half of the study. These reductions were partially made up
in the latter half of the study, but overall do not adequately compensate for the initial loss. There were
no statistical changes in body weight, body weight gain, food consumption or food efﬁciency
associated with administration of (1R,2S,5R)-isopulegol in male rats at all doses or in Groups 2 and 3
female rats.
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5.1.2. 90-Day oral toxicity study
A 90-day dietary study was performed with (1R,2S,5R)-isopulegol [FL-no: 02.067] (Koetzner, 2013).
The study was performed according to OECD Test Guideline 408 (OECD, 1998) and GLP.
CRL Sprague–Dawley CD IGS rats (10 per sex per group) were exposed to (1R,2S,5R)-isopulegol
(microencapsulated in acacia gum) via the feed at dietary levels of approximately 3,000 mg (Group 3),
25,000 mg (Group 4) and 50,000 mg (Group 5) microencapsulated isopulegol-containing acacia gum/
kg feed; approx 20% of this material was isopulegol and 80% was acacia gum. Two control groups
received a feed containing 0 or 50,000 mg acacia gum/kg feed (groups 1 and 2) without isopulegol.
The test substance was considered stable under the conditions of storage over the course of this
study. The mean overall daily intakes of microencapsulated isopulegol-containing acacia gum were 0,
190, 1,750 and 3,500 mg/kg bw per day in male rats and 0, 190, 1,760 and 3,530 mg/kg per day for
the female animals in groups 1 and 2 (controls), 3, 4 and 5, respectively.
There were no mortalities, clinical or ophthalmological changes attributable to (1R,2S,5R)-isopulegol
administration, and there were no consistent dose-related or toxicologically relevant changes that
could be attributed to exposure to isopulegol in clinical chemistry or urinalysis parameters. In males,
there was a dose-related decrease in eosinophils, which reached statistical signiﬁcance in the highest
dose group (down with 36%), compared with the vehicle control. Also, decreases in the other
lymphocyte populations and in the total white blood cell counts were observed in the mid- and high-
dose group males. However, for these changes, statistical signiﬁcance was not reached. There were no
consistent dose-related changes in other haematological parameters in males or in any of the
haematological parameters in females.
Signiﬁcant reductions in food consumption were observed in males administered the highest dose
compared with basal and carrier control groups, and in all female groups administered (1R,2S,5R)-
isopulegol compared with the carrier control group. Signiﬁcant decreases in male body weight and
male and female body weight gain were considered the result of decreased food intake and related to
the high dietary concentrations of (1R,2S,5R)-isopulegol. There were no food consumption or food
efﬁciency changes in carrier control group males and females compared with basal control groups for
each sex. Since there were no consistent statistically signiﬁcant changes in food efﬁciency in males and
females, the body weight changes in males and females were considered to be related to the reduced
feed intake and of no toxicological signiﬁcance.
There were no clinical pathology or macroscopic ﬁndings attributed to the administration of
(1R,2S,5R)-isopulegol. Microscopic ﬁndings were observed in male rats administered (1R,2S,5R)-
isopulegol and included an increased incidence and severity of chronic progressive nephropathy and
tubular hyaline droplets in Groups 4 and 5 male kidneys compared with the two control groups (1 and
2). These ﬁndings, along with granular casts in the renal tubules of males administered the highest
dose of 3,500 mg/kg bw per day (1R,2S,5R)-isopulegol, are consistent with alpha-2u-globulin
nephropathy. There was no hyaline droplet accumulation or granular cast observation in the kidneys of
the control group males or males administered the lowest concentration of (1R,2S,5R)-isopulegol.
There were no ﬁndings in the kidneys of basal control, carrier or (1R,2S,5R)-isopulegol-treated female
rats, consistent with alpha-2u-globulin nephropathy. No other dose-related histopathological ﬁndings
were reported in either males or females.
Increased relative kidney weights in males administered the two highest dietary doses were
considered the result of (1R,2S,5R)-isopulegol administration, possibly related to the histological
ﬁndings in the kidneys of male rats. Increases in relative male and female liver weights, at the two
highest administered dietary doses, were without accompanying histological changes, and were
considered toxicologically insigniﬁcant, also because in the clinical chemistry no indications of liver
toxicity were observed.
No further evidence was provided that the renal changes in male rats were the result of (male rat
speciﬁc) alpha-2u-globulin accumulation. Therefore, the Panel decided that these renal changes should
be taken into account for the derivation of a NOAEL from this study, together with the decreased
lymphocyte cell counts (observed in male rats at the two highest dose levels). Under the conditions of
the study and based on the renal and haematological ﬁndings in male animals, the NOAEL for
administration of (1R,2S,5R)-isopulegol-containing acacia gum in the diet was determined to be
190 mg/kg bw per day in male rats. Since the microencapsulated test material was analysed to contain
20% (1R,2S,5R)-isopulegol (the rest was acacia gum), the equivalent NOAEL for (1R,2S,5R)-isopulegol
(neat) in the diet is calculated to be 38 mg/kg bw per day.
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6. Application of the procedure
6.1. Application of the procedure to isopulegone and two structurally
related ﬂavouring substances by JECFA (2001a)
Step 1
According to JECFA, (1R,2S,5R)-isopulegol [FL-no: 02.067] and (1R,2S,5R)-isopulegyl acetate
[FL-no: 09.219] are allocated to structural class I and (2R,5S)-isopulegone [FL-no: 07.067] is allocated
to structural class II (Cramer et al., 1978).
Step 2
At the estimated levels of intake, none of the three ﬂavouring substances would be expected to
saturate the available metabolic detoxication pathways, but they are not completely metabolised to
innocuous products. JECFA evaluated these substances, together with pulegone via the B-side of the
Procedure.
Step B3
The daily per capita intakes of all the substances in this group are below the threshold for human
intake for each class (class I, 1,800 lg; class II, 540 lg). Accordingly, evaluation of these substances
proceeded to step B4.
Step B4
The lack of toxicity of pulegone at low levels of intake was demonstrated in a 90-day study in rats
fed peppermint oil that contained 1.1% pulegone. The no observed effect level (NOEL) of 40 mg/kg
bw per day for nephropathy associated with hyaline droplets at a higher dose (Spindler and Madsen,
1992) corresponds to a NOEL of 0.44 mg/kg bw per day (26 mg/person per day) for pulegone. This
NOEL is more than 10,000 times the intake of 0.033 lg/kg bw per day from use of pulegone as a
ﬂavouring agent. Since pulegone is metabolised to menthofuran [FL-no: 13.035], data on pulegone
can be used to evaluate the safety of menthofuran, although the latter was about three times more
hepatotoxic after single doses (Gordon et al., 1982). (2R,5S)-isopulegone [FL-no: 07.067] was less
hepatotoxic than pulegone after single doses. The NOEL of 0.44 mg/kg bw per day for pulegone in the
90-day study is more than 1,000 times the daily intake of 0.4 lg/kg bw per day from use of
menthofuran as a ﬂavouring agent. (2R,5S)-isopulegone [FL-no: 07.067], (1R,2S,5R)-isopulegol [FL-no:
02.067] and (1R,2S,5R)-isopulegyl acetate [FL-no: 09.219] are expected to be partly metabolised to
menthofuran. Even if these compounds are assumed to be metabolised to menthofuran to the same
extent as pulegone, however, the NOEL for pulegone is more than 10,000 times the daily intake from
use of (2R,5S)-isopulegone and (1R,2S,5R)-isopulegyl acetate and is more than 1,000 times the daily
intake from use of (1R,2S,5R)-isopulegol as a ﬂavouring agent.
In conclusion, JECFA evaluated all four substances as to be of no safety concern at the estimated
level of intake as a ﬂavouring substance based on the MSDI approach.
The evaluations of these ﬂavouring substances by JECFA are summarised in Appendix E Table E.1.
6.2. EFSA considerations
The Panel agrees with JECFA (2001a) that the candidate ﬂavouring substances in this FGE should
be evaluated via the B-side of the Procedure. However, the Panel decided that pulegone should not be
considered as a supporting substance for the isopulegone-related candidate substances in this FGE
(see Section 2.2.1). A NOAEL of 38 mg/kg bw per day has become available for the candidate
substance (1R,2S,5R)-isopulegol which can be used to evaluate the three candidate substances in this
FGE. Comparing the exposure estimates (MSDI) for (1R,2S,5R)-isopulegol, (1R,2S,5R)-isopulegyl
acetate and (2R,5S)-isopulegone [FL-no: 02.067, 07.067 and 09.219] with the NOAEL of (1R,2S,5R)-
isopulegol, adequate margins of safety of 2.7 9 103, 1.9 9 107 and 1.9 9 108, respectively, can be
calculated. Therefore, the Panel concluded that these three substances do not pose a safety concern
at the current levels of intake as ﬂavouring substances, based on the MSDI approach.
7. Conclusions
Following a request from the European Commission, the CEF Panel was asked to deliver a scientiﬁc
opinion on the implications for human health of chemically deﬁned ﬂavouring substances used in or on
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foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the JECFA
evaluations of ﬂavouring substances assessed since 2000, and to decide whether no further evaluation
is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These ﬂavouring substances
are listed in the Union List, which was adopted by Commission Regulation (EU) No 872/2012 and its
consecutive amendments.
In FGE.57, EFSA considered a group of (2R,5S)-isopulegone [FL-no: 07.067] and three other
substances, (1R,2S,5R)-isopulegol [FL-no: 02.067], (1R,2S,5R)-isopulegyl acetate [FL-no: 09.219] and
p-mentha-1,4(8)-dien-3-one [FL-no: 07.127] evaluated by JECFA at its 55th meeting. Apart from
[FL-no: 02.067, 07.067, 07.127 and 09.219], two more substances were evaluated by JECFA in the
group of pulegone and structurally related substances. These two substances, pulegone (JECFA-no:
753) and menthofuran (JECFA-no: 758), are in Annex III of Regulation (EC) No 1334/2008 of the
European Parliament and of the Council1 and accordingly cannot be used as ﬂavouring substances in
the EU. p-Mentha-1,4(8)-dien-3-one [FL-no: 07.127] is no longer supported by the ﬂavour industry and
has not been evaluated in this FGE. Therefore, the present revision of FGE.57, FGE.57Rev1, considers
only three ﬂavouring substances evaluated by JECFA.
Contrary to JECFA, the Panel decided not to use pulegone as a supporting substance for
FGE.57Rev1.
On the basis of available data on (1R,2S,5R)-isopulegol [FL-no: 02.067], the Panel concluded that
for (1R,2S,5R)-isopulegol [FL-no: 02.067], (2R,5S)-isopulegone [FL-no: 07.067] and (1R,2S,5R)-
isopulegyl acetate [FL-no: 09.219] there is no concern for genotoxicity and, therefore, they can be
evaluated through the Procedure.
The Panel agrees with JECFA that these substances should be evaluated via the B-side of the
Procedure.
From a newly submitted 90-day subchronic oral toxicity study, a NOAEL of 38 mg/kg bw per day
can be derived for isopulegol. Based on this, for substances (1R,2S,5R)-isopulegol [FL-no: 02.067],
(2R,5S)-isopulegone [FL-no: 07.067] and (1R,2S,5R)-isopulegyl acetate [FL-no: 09.219], adequate
margins of safety can be derived and these three substances would not pose a safety concern at the
current levels of exposure, based on the MSDI approach.
In order to determine whether the conclusion for the three JECFA evaluated substances can be
applied to the materials of commerce, it is necessary to consider the available speciﬁcations. Adequate
speciﬁcations including complete purity criteria and identity became available for all the JECFA-
substances evaluated in this FGE.
Thus, the Panel agrees with the JECFA conclusion on three substances [FL-no: 02.067, 07.067,
09.219]: ‘No safety concern at estimated levels of intake as ﬂavouring substances based on the MSDI
approach’.
For (1R,2S,5R)-isopulegol [FL-no: 02.067], (2R,5S)-isopulegone [FL-no: 07.067] and (1R,2S,5R)-
isopulegyl acetate [FL-no: 09.219], the ﬂavour industry submitted use levels for normal and maximum
use. Based on these normal use levels, the mTAMDI values were calculated. (1R,2S,5R)-Isopulegyl
acetate [FL-no: 09.219] has the mTAMDI intake estimate below the threshold of concern for its
structural class. For (1R,2S,5R)-isopulegol [FL-no: 02.067] and (2R,5S)-isopulegone [FL-no: 07.067],
the mTAMDI values are above the toxicological thresholds of concern for their structural classes of
1,800 and 540 lg/person per day, respectively. Therefore, for these two substances more reliable data
on use and use levels are required in order to ﬁnalise their evaluation. On the basis of such additional
data, [FL-no: 02.067 and 07.067] should be reconsidered using the Procedure. Following this
procedure, additional toxicological data might become necessary.
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1) EFFA (European Flavour Association), 2014. E-mail from EFFA to FLAVIS Secretariat, Danish
Food Institute, Technical University of Denmark, dated 2 June 2014. Information on
substances [FL-no: 02.067, 07.067, 07.127 and 09.219] in FGE.57Rev1. FLAVIS/8.241.
2) EFFA (European Flavour Association), 2016a. Updated Addendum of Additional Data Relevant
to the Flavouring Group Evaluation of the Chemical Group 8 (Annex I of 1565/2000/EC)
Consideration of Isopulegol evaluated by JECFA (46th meeting) as evaluated by EFSA in
FGE.57 (2009). 02 September 2016. Unpublished report submitted by EFFA to EFSA.
3) EFFA (European Flavour Association), 2016b. Letter submitted from EFFA to EFSA in relation
to the ﬂavouring substance p-mentha-1,4(8)-dien-3-one [FL-no: 07.127]. 03 October 2016.
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4) EFFA (European Flavour Association), 2017. Correspondence submitted from EFFA to EFSA in
relation to the use levels of substances from FGE.57. 19 January 2017.
5) Koetzner L, 2013. Isopulegol (microencapsulated): a 90-day dietary study in rats. Product
Safety Labs. Study no. 35334. December 2, 2013. Unpublished report submitted by EFFA to
FLAVIS Secretariat.
6) Mendes O, 2012. Isopulegol: palatability/toxicity study: a 14-day dietary study in rats.
Product Safety Labs. Study no. 34780. September 28, 2012. Unpublished report submitted
by EFFA to FLAVIS Secretariat.
7) Roy S, 2015. Isopulegol (CAS# 89-79-2): In vitro mammalian cell micronucleus assay in
human peripheral blood lymphocytes (HPBL). Study number: AD90NJ.348.BTL. BioReliance
Laboratories Ltd., Rockville, Maryland, USA. Unpublished report to the International
Organization of the Flavor Industry, Brussels, Belgium.
8) Schulz M, 2010. L-Isopulegol: Salmonella typhimurium/Escherichia coli reverse mutation
assay (Standard Plate Test and Preincubation Test). Project No.: 40M0358/10M055. BASF SE,
Ludwigshafen, Germany. Unpublished report provided by agreement to the International
Organization of the Flavor Industry.
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Abbreviations
Bw body weight
CAS Chemical Abstract Service
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CoE Council of Europe
DMSO dimethyl sulfoxide
EFFA European Flavour Association
EMA European Medicines Agency
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GC gas chromatography
GLP Good Laboratory Practice
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HPBL human peripheral blood lymphocytes
HPLC high-performance liquid chromatography
IARC International Agency for Research on Cancer
ID Identity
IOFI International Organization of the Flavour Industry
IR infrared
JECFA Joint FAO/WHO Expert Committee on Food Additives
MS mass spectrometry
MSDI maximised survey-derived daily intake
mTAMDI modiﬁed theoretical added maximum daily intake
NOAEL no observed adverse effect level
NOEL no observed effect level
NTP National Toxicology Program
OECD Organisation for Economic Co-operation and Development
PHA phytohaemagglutinin
SCF Scientiﬁc Committee on Food
WHO World Health Organization
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Appendix A – Procedure for the safety evaluation
The approach for a safety evaluation of chemically deﬁned ﬂavouring substances as referred to in
Commission Regulation (EC) No 1565/2000, named the ‘Procedure’, is shown in schematic form in
Figure A.1. The Procedure is based on the Opinion of the Scientiﬁc Committee on Food expressed on 2
December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995,
1996, 1997, 1999).
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in the
Procedure is the subdivision of ﬂavourings into three structural classes (I, II and III) for which
thresholds of concern (human exposure thresholds) have been speciﬁed. Exposures below these
thresholds are not considered to present a safety concern.
Class I contains ﬂavourings that have simple chemical structures and efﬁcient modes of
metabolism, which would suggest a low order of oral toxicity. Class II contains ﬂavourings that have
structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises
ﬂavourings that have structural features that permit no strong initial presumption of safety, or may
even suggest signiﬁcant toxicity (Cramer et al., 1978). The thresholds of concern for these structural
classes of 1,800, 540 or 90 lg/person per day, respectively, are derived from a large database
containing data on subchronic and chronic animal studies (JECFA, 1996).
In step 1 of the Procedure, the ﬂavourings are assigned to one of the structural classes. The
further steps address the following questions:
• Can the ﬂavourings be predicted to be metabolised to innocuous products5 (step 2)?
• Do their exposures exceed the threshold of concern for the structural class (steps A3 and B3)?
• Are the ﬂavourings or their metabolites endogenous6 (step A4)?
• Does a NOAEL exist on the ﬂavourings or on structurally related substances (steps A5 and B4)?
In addition to the data provided for the ﬂavouring substances to be evaluated (candidate
substances), toxicological background information available for compounds structurally related to the
candidate substances is considered (supporting substances), in order to assure that these data are
consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to ﬂavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on speciﬁc ﬂavourings warranted
such actions.
5 ‘Innocuous metabolic products’: products that are known or readily predicted to be harmless to humans at the estimated
intakes of the ﬂavouring agent (JECFA, 1997).
6 ‘Endogenous substances’: intermediary metabolites normally present in human tissues and ﬂuids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997).
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Appendix C – Absorption, distribution, metabolism and elimination
Interconversion of pulegone and isopulegone: the JECFA evidence
The Panel reassessed the earlier position of EFSA (taken over from a JECFA evaluation) that:
‘There are some indication that, to a small extent, isopulegone may be isomerised to pulegone
(Gordon et al., 1987; McClanahan et al., 1988). Therefore, the Panel considered it relevant to include
data on pulegone and the metabolically related menthofuran. Accordingly, in the consideration of the
three substances in this FGE (isopulegol [FL-no: 02.067], isopulegone [FL-no: 07.067] and isopulegyl
acetate [FL-no: 09.219]) the Panel will take into account the SCF Opinion on pulegone and
menthofuran (SCF, 2002), later revised by EFSA based on additional data (EFSA, 2005)’ (EFSA, 2009).
The above evaluations, based on a review by Speijers (2001) for the 55th JECFA meeting, deal with
the safety evaluation of (iso)pulegone. They suggest that isopulegone and pulegone can be
interconverted, in vivo, in animals.
In the Speijers review, however, no evidence is presented for conversion of isopulegone to
pulegone. Indeed no such evidence could be retrieved from literature since publications on the
metabolism of isopulegone were not found.
All evidence quoted to support the conversion of pulegone to isopulegone was based on the
publication by Gordon et al. (1987). In this article, it is mentioned that ‘Isomerization of pulegone to
isopulegone does occur during incubation of pulegone with mouse liver microsomes’. However, the
authors do not give any evidence to support that statement, nor any reference to earlier ﬁndings
either. In fact, no evidence from the literature could be retrieved to support this statement.
In a more recent review on pulegone metabolism (Gordon and Khojasteh, 2014), isopulegone is no
longer included as a pulegone metabolite in the scheme of pulegone metabolism. Speijers (2001)
refers to the publication by McClanahan et al. (1988), where it is presented the proposed mechanism
of cytochrome P450-catalysed formation of (deuterated) menthofuran-d3 from pulegone-d3. In this
article, the potential conversion to isopulegone is not discussed.
In conclusion, no experimental data could be identiﬁed to support the concept of interconversion of
isopulegone and pulegone.
Metabolism of isopulegone
No data on the metabolism of isopulegone could be retrieved from the literature. It can be
assumed that cytochrome P450-mediated oxidation may take place at various positions in the
molecule, and that subsequent conjugation with sulfate or glucuronic acid occurs. However, no
experimental data are available.
Metabolism of pulegone
Engel (2003) extensively studied the metabolism of pulegone in human volunteers. In this study, 35
mg of R-(+)-pulegone and 70 mg of S-(–)-pulegone were administered to three male and three female
volunteers and urine was collected 24 h after oral dosing under carefully controlled conditions (Engel,
2003). The urine was treated with b-glucuronidase/arylsulfatase to release conjugates, and extracted
by diethyl ether into several fractions. It was compared to urine collected in a control period from the
same volunteers. High-performance liquid chromatography (HPLC) and high-resolution gas
chromatography–mass spectrometry (GC–MS) were used for the identiﬁcation and the semiquantitative
determination of the metabolites. The identiﬁcation of all metabolites was conﬁrmed by comparison
with synthesised reference compounds. The major metabolites of S-(–)-pulegone are (conjugates of)
8-hydroxymenthone (M1), 1-hydroxymenthone (M2) and 10-hydroxypulegone (M4). Minor metabolites
are piperitone (M5) and 3-p-menthen-8-ol (M6). The author identiﬁed menthol (M3) as a pulegone
metabolite. Interestingly, Engel (2003) found only traces of menthofuran in the urine. On eventual,
other metabolites the author states: ‘there were traces of other compounds present only in test urines;
however, due to their low amount it was impossible to identify them by interpreting the mass
spectrometric data. Because their amount was much lower compared to the metabolites identiﬁed,
they might also stem from impurities in pulegone and therefore might not be metabolites of the latter’.
Therefore, Engel (2003), in this very thorough investigation, did not ﬁnd isopulegone as a pulegone
metabolite.
Chen et al. (2003) extensively investigated the disposition of R-(+)-pulegone in mice and rats and
did not mention the presence of isopulegone.
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Da Rocha et al. (2012) in a study on the action of R-(+)-pulegone on the urinary bladder evaluated
the metabolism of pulegone, but did not mention isopulegone as metabolite in urine.
Thomassen et al. (1991) did not ﬁnd isopulegone or isopulegol as biliary metabolites in rats orally
administered with pulegone.
Madyastha and Gaikwad (1998) reported that they identiﬁed isopulegone in rat urine after dosing
with S-(–)-pulegone. The amount of pulegone recovered was over 99%. To demonstrate the presence
of isopulegone, the authors analysed the urine and identiﬁed the substance in ‘fractions containing
small quantities of compounds’. The outcome of the GC–MS analysis revealed the presence of
molecular ion peaks of six metabolites’ and isopulegone was one of them. The authors conﬁrmed this
analytical outcome by co-injecting authentic standards along with the total fraction used for GC–MS
analysis and observing the enhancement of the corresponding peaks. In any case and if indeed
present, the quantity of isopulegone as a metabolite of pulegone was very minor. However, the
Panel noted that in this publication it is not investigated the possibility that isopulegone identiﬁed in
urine might be a small impurity of the initially administered pulegone preparation.
Conclusion
Based on the information presented above, the Panel concluded that there is no (convincing)
evidence for interconversion of pulegone and isopulegone.
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